Skip to main content
SpringerLink
Log in

Quality-of-Life Issues and Economic Burden of Psoriasis and Atopic Dermatitis

Rationale for Treatment

  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Summary

Both psoriasis and atopic dermatitis are common skin disorders that have profound social and economic effects on the patients and their families. Surveys of the effects of these diseases have demonstrated their interference with social life, sport, caring for the home, personal and sexual relationships, and the ability to work. These effects are similar across many cultures. Methods of measuring the impact of psoriasis and atopic dermatitis on quality of life include disease-specific indices such as the Psoriasis Disability Index, specialty-specific indices such as the Dermatology Life Quality Index, general health measures such as the UK Sickness Impact Profile, and utility measures. Both diseases score more highly than other skin conditions, and result in handicap levels equivalent to those experienced by patients with nondermatological diseases such as hypertension and angina. The use of these measures in psoriasis and atopic dermatitis has shown an improvement in handicap levels resulting from inpatient admission and from treatment with cyclosporin. These diseases can have an immediate effect on earnings and a long term effect on career choices and employment opportunities. Cost analysis of management strategies highlights the financial advantages of daycare outpatient treatment centres and provides a financial ranking of the different topical and systemic approaches to the treatment of psoriasis. The costs of treatment must be considered in relation to the degree of benefit gained in terms of handicap reduction and restored earning capacity, and not simply in terms of the unit cost of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Russell PS. Dermatology in the Oregon Plan with implications for health care plans in other states. Arch Dermatol 1994; 130: 709–12

    Article  PubMed  CAS  Google Scholar 

  2. Ingram JT. The significance and management of psoriasis. BMJ 1954; II: 823–8

    Article  Google Scholar 

  3. Ginsburg IH, Link BG. Feelings of stigmatisation in patients with psoriasis. J Am Acad Dermatol 1989; 20: 53–63

    Article  PubMed  CAS  Google Scholar 

  4. Ramsay B, O’Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol 1988; 118: 118–201

    Article  Google Scholar 

  5. Gupta MA, Gupta AK, Ellis CN, et al. Some psychosomatic aspects of psoriasis. Adv Dermatol 1990; 5: 21–32

    PubMed  CAS  Google Scholar 

  6. Roenigk RK, Roenigk HH. Sex differences in the psychological effects of psoriasis. Cutis 1978; 21: 529–33

    PubMed  CAS  Google Scholar 

  7. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236–44

    Article  PubMed  CAS  Google Scholar 

  8. Yasuda H, Kobayashi H, Ohkawara A. A survey of the social and psychological effects of psoriasis. Jpn J Dermatol 1990; 100: 1167–71

    CAS  Google Scholar 

  9. Haisma HH, Kaptain AA, Thio B, et al. Social aspects of psoriasis, the Psoriasis Disability Index. Presentation at 6th International Congress on Dermatology and Psychiatry; April 20–22: Amsterdam: 1995

  10. Long CC, Funnell CM, Collard R, et al. What do members of the National Eczema Society really want? Clin Exp Dermatol 1993; 18: 516–22

    Article  PubMed  CAS  Google Scholar 

  11. Lawson V, Lewis-Jones MS, Owens RG, et al. Family impact of childhood atopic eczema. Br J Dermatol 1995; 133Suppl. 45: 19

    Google Scholar 

  12. Finlay AY. Measures of the effect of severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol. In press

  13. Marks R, Barton SP, Shuttleworth D, et al. Assessment of disease progress in psoriasis. Arch Dermatol 1989; 125: 235–40

    Article  PubMed  CAS  Google Scholar 

  14. Finlay AY. Measurement of disease activity and outcome in atopic dermatitis. J Dermatol Treat. In press

  15. Fredriksson T, Pettersson U. Severe psoriasis — oral therapy with a new retinoid. Dermatologica 1978; 157: 238–44

    Article  PubMed  CAS  Google Scholar 

  16. Sowden JM, Berth-Jones J, Ross JS, et al. A multicentre, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of cyclosporin in adult patients with severe refractory atopic dermatitis. Lancet 1991; 338: 137–40

    Article  PubMed  CAS  Google Scholar 

  17. Finlay AY, Kelly SE. Psoriasis — an index of disability. Clin Exp Dermatol 1987; 12: 8–11

    Article  PubMed  CAS  Google Scholar 

  18. Root S, Kent G, Al-Abadie MSK. The relationship between disease severity, disability and psychological distress in patients undergoing PUVA treatment for psoriasis. Dermatology 1994; 189: 234–7

    Article  PubMed  CAS  Google Scholar 

  19. Kent G, Al-Absadie M. The Psoriasis Disability Index — further analyses. Clin Exp Dermatol 1987; 12: 8–11

    Article  Google Scholar 

  20. Finlay AY, Khan GK, Luscombe DK, et al. Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis. Br J Dermatol 1990; 123: 751–6

    Article  PubMed  CAS  Google Scholar 

  21. Salek MS, Finlay AY. Cyclosporin improves quality of life in psoriasis — does this matter? Br J Dermatol 1993; 129Suppl. 42: 32

    Google Scholar 

  22. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–6

    Article  PubMed  CAS  Google Scholar 

  23. Kurwa HA, Finlay AY. Dermatology inpatient admission greatly improves life quality. Br J Dermatol. In press

  24. Salek MS, Finlay AY, Luscombe DK, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. Br J Dermatol 1993; 129: 422–30

    Article  PubMed  CAS  Google Scholar 

  25. Salek MS, Luscombe DK, Walker SR, et al. Cardiovascular disease and quality of life. Br J Clin Pharmacol 1988; 26: 628

    Google Scholar 

  26. Simpson NB. Social and economic aspects of acne and the cost-effectiveness of isotretinoin. J Dermatol Treat 1993; 4Suppl. 2: S6–9

    Article  Google Scholar 

  27. Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942–9

    Article  PubMed  CAS  Google Scholar 

  28. Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporin in severe childhood atopic dermatitis: a multicentre study. Br J Dermatol 1994; 131Suppl. 44: 25

    Google Scholar 

  29. Mathias CGT. The cost of occupational skin disease. Arch Dermatol 1985; 121:332–4

    Article  PubMed  CAS  Google Scholar 

  30. Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med 1995; 20: 425–9

    Article  Google Scholar 

  31. Molin L. Psoriasis. Acta Derm Venereol (Stockh) 1973; 53Suppl. 72: 1–125

    CAS  Google Scholar 

  32. Larko O, Swanbeck G. Psoriasis treatment and a day-care centre; clinical aspects and an attempt at a cost-benefit analysis. Acta Derm Venereol (Stockh) 1982; 62: 413–8

    CAS  Google Scholar 

  33. Finlay AY, Bryden JS. Integrated in-patient and out-patient dermatology management. Clin Exp Dermatol 1989; 14: 7–11

    Article  PubMed  CAS  Google Scholar 

  34. McCarthy M. An evaluation of a day-care service for psoriasis patients. M Soc Sci thesis, University College Dublin, 1987

  35. Sander HM, Morris LF, Phillips CM, et al. The annual cost of psoriasis. J Am Acad Dermatol 1993; 28: 422–5

    Article  PubMed  CAS  Google Scholar 

  36. Krueger GG, Bergstresser PR, Lowe NJ, et al. Psoriasis. J Am Acad Dermatol 1984; 11: 937–47

    Article  PubMed  CAS  Google Scholar 

  37. Carmichael AJ, Motley RJ, Finlay AY, et al. Methotrexate associated hepatic complications and monitoring protocols in UK dermatology. Br J Dermatol 1992; 127Suppl. 40: 18

    Google Scholar 

  38. Cork M. Economic considerations in the treatment of psoriasis. Dermatol Practice 1993; Jan–Feb: 16–20

    Google Scholar 

  39. Wattie JM. Eczema and work. Exchange 1994; 72: 10–11

    Google Scholar 

  40. Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: Who cares? Who pays? J Am Acad Dermatol 1993; 28: 699–703

    Article  PubMed  CAS  Google Scholar 

  41. Herd RM, Tidman MJ, Hunter JAA, et al. The economic burden of atopic eczema: a community and hospital based assessment. Br J Dermatol 1994; 131Suppl. 44: 34

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Wales College of Medicine, Heath Park, Cardiff, Wales, CF4 4XN, UK

    A. Y. Finlay

Authors
  1. A. Y. Finlay
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Finlay, A.Y. Quality-of-Life Issues and Economic Burden of Psoriasis and Atopic Dermatitis. Clin. Drug Invest. 10 (Suppl 1), 1–6 (1995). https://doi.org/10.2165/00044011-199500101-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-199500101-00003

Keywords

Search

Navigation